Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
5 Biotech Stocks That Have Gained More Than 200% in 2020
10:32am, Tuesday, 29'th Dec 2020
Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.
Intellia Therapeutics: The Smallest Of The Big 3 CRISPR Companies Has Big Potential
09:39am, Wednesday, 23'rd Dec 2020
Intellia is overshadowed a bit by its cousins Editas & CRISPR Therapeutics, however Intellia has a rich pipeline that looks to be focused on a few opportunities outside of its competition. The stock h
Demonstrates modularity of Intellia's in vivo liver insertion technology to durably restore protein, compared to traditional gene therapy
CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), is presenting new preclinical data in support of NTLA-5001, the company's wholly owned Wilms' Tumor 1 (WT
CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
09:30pm, Tuesday, 01'st Dec 2020
CAMBRIDGE, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
04:01pm, Monday, 30'th Nov 2020
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology
Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments
07:30am, Wednesday, 11'th Nov 2020
Funding from the Bill & Melinda Gates Foundation to develop safe, scalable and accessible non-viral treatments for sickle cell patients
NTLA-2001: First single-course therapy that potentially halts and reverses ATTR progression
Intellia Therapeutics, Inc.'s (NTLA) CEO John Leonard on Q3 2020 Results - Earnings Call Transcript
01:54pm, Thursday, 05'th Nov 2020
Intellia Therapeutics, Inc.'s (NTLA) CEO John Leonard on Q3 2020 Results - Earnings Call Transcript
Intellia Therapeutics Announces Third Quarter 2020 Financial Results
07:30am, Thursday, 05'th Nov 2020
CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company Updates
07:30am, Thursday, 29'th Oct 2020
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology
Crispr Therapeutics’ Gene-Edited Treatment Stopped Cancer in Some Patients
02:02pm, Wednesday, 21'st Oct 2020
Using a gene-editing technique that won a recent Nobel Prize, Crispr Therapeutics cleared blood cancers in patients with off-the-shelf immune cells. Previously, a patient’s own cells were required.
The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings
12:00am, Wednesday, 21'st Oct 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 20)
Aileron Therapeutics Inc (...
Chardan Capital Believes Intellia Therapeutics (NASDAQ: NTLA) Still Has Room to Grow - Markets
03:45pm, Monday, 19'th Oct 2020
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a
